| Stereochemistry | ACHIRAL |
| Molecular Formula | C18H19N3O2 |
| Molecular Weight | 309.3624 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
COC1=CC2=C(C=C1OC)C(=NN=C(C)C2)C3=CC=C(N)C=C3
InChI
InChIKey=WWQDEXGFYVSTCX-UHFFFAOYSA-N
InChI=1S/C18H19N3O2/c1-11-8-13-9-16(22-2)17(23-3)10-15(13)18(21-20-11)12-4-6-14(19)7-5-12/h4-7,9-10H,8,19H2,1-3H3
| Molecular Formula | C18H19N3O2 |
| Molecular Weight | 309.3624 |
| Charge | 0 |
| Count |
MOL RATIO
1 MOL RATIO (average) |
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
Nerisopam [EGIS 6775, GYKI 52322] is a novel 2,3-benzodiazepine derivative with both anxiolytic and antipsychotic activity in animal studies. Nerisopam induces rapid, intense expression of Fos-like immunoreactivity in the rostral, dorsomedial and lateral parts of the striatum in the rat. The striatal neurons are the primary targets of this anxiolytic and antipsychotic drug in the central nervous system. Nerisopam does not bind to the central dopamine receptors, but it shows affinity to the 5-HT1 receptors (IC50 = 7.1 x 10(-6) mol/l) and inhibits brain cAMP-phosphodiesterase (IC50 = 2.4 x 10(-5) mol/l). Nerisopam development for the treatment of anxiety disorder and schizophrenia were discontinued in phase 1.
CNS Activity
Originator
Approval Year
PubMed
Patents
Sample Use Guides
Nerisopam 3, 10 and 30 mg/kg PO or IP dose-dependently reduced spontaneous motor activity in both rats and mice.
Route of Administration:
Other
